BMO Capital analyst Evan Seigerman upgraded Replimune (REPL) to Market Perform from Underperform with a price target of $11, up from $2. The firm ...

WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

Qure (QURE) shares drop after FDA questions AMT-130 data for Huntington’s disease, delaying BLA submission. Read more here.

People find World-Herald stories in many ways. Family and friends of Johnathan Wallace release balloons at a vigil for Wallace in the parking lot outside of Anytime Laundry in Omaha on Tuesday, Sept.